NASDAQ:LUCD

Lucid Diagnostics Stock Insider Trading

Healthcare > Medical - Devices

Buy LUCD

*Your capital is at risk

$1.01

-0.0250 (-2.43%)

At Close: Jun 03, 2026

Lucid Diagnostics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 22.4M and sold 6.74M LUCD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	22.4M shares
● Sell	6.74M shares
76% Buy Activity Strong Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 15, 2024 Sell	Common Stock J-Other	Pavmed Inc. 10 Percent Owner	10% Owner	3 331 747 Value: $0
Jan 26, 2024 Buy	Common Stock J-Other	Pavmed Inc. 10 Percent Owner	10% Owner	3 331 771 Value: $4.68M
Jan 26, 2024 Buy	Common Stock J-Other	Pavmed Inc. 10 Percent Owner	10% Owner	3 331 771 Value: $4.68M
Sep 26, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	10 000 Value: $14.7K
Sep 26, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	10 000 Value: $14.3K
Sep 26, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	9 747 Value: $14.1K
Sep 26, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	10 000 Value: $14.7K
Sep 26, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	10 000 Value: $14.3K
Sep 26, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	9 747 Value: $14.1K
Sep 25, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	200 Value: $286
Sep 25, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	200 Value: $286
Sep 21, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	100 Value: $144
Sep 21, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	100 Value: $144
Sep 21, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	100 Value: $144
Sep 21, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	100 Value: $144
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	3 405 Value: $5K
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	412 Value: $593
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	3 405 Value: $5K
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	412 Value: $593
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	3 405 Value: $5K
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	412 Value: $593
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	3 405 Value: $5K
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	412 Value: $593
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	3 405 Value: $5K
Sep 20, 2023 Sell	Common stock S-Sale	Lapidus Stanley Director	Director	412 Value: $593

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LUCID DIAGNOSTICS INC.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an...

Read Full Profile Here